ClinicalTrials.gg
CompletedNCT03929510B7981011Updated Jul 24, 2019

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.

A Phase 1 interventional study of 14C-PF-06651600 and 14C-PF-06651600 IV in Healthy Volunteers, sponsored by Pfizer. Completed at 2 sites in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2019, 7 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study will investigate the absorption, distribution, metabolism and excretion (ADME) of 14C PF-06651600 and characterize plasma, fecal and urinary radioactivity and identify any metabolites, if possible, of 14C PF-06651600 in humans.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Phase 1
  • Male
  • healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants who are healthy as determined by medical evaluation including a detailed medical history, full physical examination, including blood pressure (BP) and pulse rate (PR) measurement, 12 lead , and clinical laboratory tests.
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

  • Known immunodeficiency disorder, including positive serology for (HIV) at screening, or a first degree relative with a hereditary immunodeficiency.
  • Infection with or viruses.
  • Participants with selected acute or chronic infections or infection history.
  • Participants have a known present or a history of other than a successfully treated or excised non basal cell or squamous cell cancer of the skin.
  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  • Use of tobacco/nicotine containing products within 3 months prior to dosing or positive urine cotinine test.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Period A

    Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600).

    Drug: 14C-PF-06651600

  • Experimental
    Period B

    Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600).

    Drug: 14C-PF-06651600 IV · Drug: PF-06651600

Interventions

  • Drug14C-PF-06651600

    Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity

  • Drug14C-PF-06651600 IV

    IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity

  • Oral solution 200mg

06

What researchers measure

Primary outcomes

  1. Mass Balance: Cumulative recovery (%) of radioactivity in urine

    Cumulative recovery (%) of radioactivity in urine.

    Time frame: from time zero to the time of last measurable concentration following oral administration of 14C PF-06651600 microtracer dose up to day 24

  2. Mass Balance: Cumulative recovery (%) of radioactivity in feces

    Cumulative recovery (%) of radioactivity in feces

    Time frame: from time zero to the time of last measurable concentration following oral administration of 14C PF-06651600 microtracer dose up to day 24

Secondary outcomes

  1. Amount (% of the administered dose) of major metabolites of PF-06651600 in plasma

    Time frame: Hour 0 up to 312 hours post-dose.

  2. Amount (% of the administered dose) of major metabolites of PF-06651600 in urine

    Time frame: Hour 0 up to 312 hours post-dose.

  3. Amount (% of the administered dose) of major metabolites of PF-06651600 in feces

    Time frame: Hour 0 up to 312 hours post-dose.

  4. Cmax

    Maximum plasma concentration

    Time frame: Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose

  5. AUClast

    Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)

    Time frame: Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose

  6. AUCinf

    Area under the plasma concentration time profile from time 0 to infinity

    Time frame: Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose

  7. Tmax

    Time for Cmax

    Time frame: Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose

  8. t1/2

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose

  9. CL (IV)

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose (apparent clearance) is influenced by the fraction of the dose absorbed.

    Time frame: Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose

  10. CL/F (oral)

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose (apparent clearance) is influenced by the fraction of the dose absorbed.

    Time frame: Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose

  11. Vss

    Steady state volume of distribution following IV infusion

    Time frame: Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose

  12. Vz/F

    Apparent volume of distribution following oral administration

    Time frame: Pre-dose, 0.25. 0.5, 1, 1.5, 2, 3.5, 4.5, 6.5, 8.5, 12.5, 24, 48, 72, 96 hours post-dose

  13. Total 14C_Urine_PO

    Total radioactivity excreted into the urine from time zero to the time of last measurable concentration following oral administration of 14C PF 06651600 microtracer dose

    Time frame: Pre-dose, Day1, day 2, day 3, day 4, day 5, day 6 and day 7 post-dose

  14. Total 14C_Urine_IV

    Total radioactivity excreted into the urine from time zero to the time of last measurable concentration following IV administration of 14C PF 06651600 microtracer dose

    Time frame: Pre-dose, Day1, day 2, day 3, day 4, day 5, day 6 and day 7 post-dose

  15. AE

    Number of subjects and number of AEs which are any untoward medical occurrence regardless of attribution to study drug in a participant who received study drug.

    Time frame: Baseline (Day 0) up to 90 days after last dose of study medication

  16. Number of participants with clinically significant changes to the physical examination

    clinically significant changes to the physical examination

    Time frame: Baseline (Day 0) up to Day 24

  17. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs (temperature, respiratory rate, pulse, systolic and diastolic blood pressure) obtained from each participant. Clinical significance of vital signs was determined at the investigator's discretion.

    Time frame: Baseline (Day 0) up to Day 24

  18. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Laboratory parameters include: hematological and chemical parameters

    Time frame: Baseline (Day 0) up to Day 24

07

Study locations

2 sites
  • PRA Health Sciences
    Groningen, 9728 NZ, Netherlands
  • PRA Health Sciences Utrecht
    Utrecht, 3584 BL, Netherlands
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jul 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 29, 2019
StartActual
Apr 23, 2019
Primary completionActual
Jul 5, 2019
CompletionActual
Jul 5, 2019
Last update
Jul 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03929510
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 29, 2019
Start date
Apr 23, 2019
Primary completion
Jul 5, 2019
Completion
Jul 5, 2019
Last update
Jul 24, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion